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Abstract
Objectives: Comparison of two doses of bio-optimized Curcuma longa extract (BCL) in the management of
symptomatic knee osteoarthritis (OA).
Methods: A prospective, randomized, 3-month, double-blind, multicenter, three-group, placebo-controlled trial
assessing Patient Global Assessment of Disease Activity (PGADA) and serum sColl2-1, a biomarker of cartilage
degradation, as co-primary endpoints. Pain on visual analog scale (VAS), Knee injury and Osteoarthritis Outcome
Score (KOOS), and paracetamol/non-steroidal anti-inflammatory drug (NSAID) consumption were used as secondary
endpoints.
Results: One hundred fifty patients with knee OA were followed for 90 days. Low and high doses of BCL showed a
greater decrease of PGADA than placebo. Analysis of sColl2-1 showed in the placebo and BCL low-dose groups, but
not in the BCL high-dose group, a transient but non-significant increase of sColl2-1 between T0 and T1. Thereafter,
in all groups, sColl2-1 decreased between T1 and T3 (all p < 0.01), but no difference between the groups was found.
Pain reduction at day 90 in the low- and high-dose BCL groups (− 29.5 mm and − 36.5 mm) was higher than that in
the placebo (− 8 mm; p = 0.018). The global KOOS significantly decreased overtime, but changes were comparable
across treatment arms. The ratio of patients with adverse events (AE) related to the product was similar in the
placebo and treatment groups, but the number of AE linked to the product was higher in the high-dose BCL group
compared to the placebo (p = 0.012).
Conclusions: BCL appeared safe and well-tolerated with no evidence of severe adverse effects. Efficacy analysis
suggested positive trends for measurements of PGADA and serum levels of an OA biomarker and showed a rapid
and significant decrease of pain in knee OA (Trial registration: NCT02909621, 21 September 2016 - retrospectively
registered).
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Key messages
 This is the first RCT respecting the clinical guidance
investigating the effects of bio-optimized Curcuma
longa extract in knee OA patients.
 Bio-optimized Curcuma longa extract is an efficient
and safe treatment to relieve pain in knee OA
patients.
 Bio-optimized Curcuma significantly decreases
paracetamol and non-steroidal anti-inflammatory
drug consumption.
Introduction
Osteoarthritis (OA) affects 240 million people globally,
about 10% of men and 18% of women [1]. Clinically, OA
is characterized by pain, transient morning stiffness, and
crepitus with joint motion, all of which deteriorate daily
quality of life, leading to sedentary and increased mor-
bidity and mortality [2, 3]. The prevalence of OA is ris-
ing due to the aging population and growing rates of
obesity [4]. Up to date, there is no curative treatment for
OA despite the availability of a large number of thera-
peutic options, including non-pharmacological, pharma-
cological, and surgical therapies. Recommendations for
the management of knee OA have been published by
numerous scientific and medical societies [5–8]. Briefly,
the association of non-pharmacological and pharmaco-
logical modalities for optimal management of OA is rec-
ommended. The pharmacological treatment of OA is
mostly symptomatic to relieve pain and improve func-
tion. The first-line pharmacological therapy is the use of
paracetamol and non-steroidal anti-inflammatory drugs
(NSAIDs). However, these drugs have a low transient an-
algesic effect on knee OA, and some meta-analysis indi-
cated the occurrence of adverse events mainly in elderly
patients with co-morbidities [9–12]. In particular, safety
profiles of oral NSAIDs remain a concern, and caution is
recommended before selecting an NSAID and dose regi-
men for a patient [13]. For that reason, it is recom-
mended to use NSAIDs at the lowest efficient dose and
intermittently [8, 14]. The unfavorable safety profiles of
commonly prescribed knee OA treatments have led pa-
tients, clinicians, and industry to seek safer alternatives
including dietary supplements like curcumin [15, 16].
Curcumin (diferuloylmethane) is the principal curcumi-
noid extracted from the Curcuma longa (turmeric) root
[17]. Curcumin has been identified as an inhibitor of the
nuclear factor-kappa β (NF-κβ) pathway and a scavenger
of reactive oxygen and nitrogen species [18, 19]. Two re-
cent meta-analyses evaluating a large number of dietary
supplements ranked curcumin as one of the most effect-
ive compounds for pain reduction in OA at short term
although the quality of evidence was very low [20, 21].
Curcuminoids showed no statistically significant
differences in the efficacy outcomes compared to NSAIDs,
but patients receiving curcuminoids were significantly less
likely to experience gastrointestinal adverse events [21]. A
meta-analysis of different turmeric derivatives including
curcumin [22] reported the positive influence of bio-
optimization by adjuvants such as piperine, liposomal de-
livery systems, phospholipid complexes of curcumin, or
use of polysorbate as an emulsifier, which is relevant since
curcumin’s low bioavailability is regarded as a major chal-
lenge for its optimal effectiveness.
Herein, we report results from a study of pharmaceutical-
grade bio-optimized Curcuma longa extract in patients
with symptomatic knee OA, which, to our knowledge, is
the first ever to have been conducted in full accordance
with the International Council for Harmonisation of Tech-
nical Requirements for Pharmaceuticals for Human use
(ICH E6).
Population and methods
Study design and selection of patients
This study included patients from Belgium enrolled by
11 physicians between September 2014 and June 2017
and was conducted by an independent contract research
organization (Artialis SA, Liège, Belgium). The main in-
clusion criteria were age between 45 and 80 years with
primary femorotibial and/or femoropatellar symptomatic
knee OA diagnosed according to the clinical and radio-
logical criteria of American College of Rheumatology
(ACR) [23]. The more symptomatic knee (with a pain
score of at least 40 mm on a 0–100-mm visual analog
scale (VAS) for at least 3 months before enrollment) was
defined as the target knee. The main exclusion criteria
were dementia or inability to give informed consent,
pregnancy or lactation, planned knee replacement sur-
gery, allergy or contraindication to curcumin, recent
trauma of the knee responsible of the symptomatic knee,
and joint disease other than OA. Use of any intra-articu-
lar injection in the target knee in the last 3 months,
symptomatic slow-acting drugs in OA (SYSADOA) in
the last month, oral corticotherapy ≥ 5mg/day in the last
3 months, products with curcuminoids extract in the last
3 months, anticoagulant (coumarinic compound), and
heparin (both relative contraindication for BCL) was also
specifically forbidden by the study protocol. Patients had
to be regular users of paracetamol and/or oral NSAIDs
to manage OA knee pain and were authorized to con-
tinue the intake of these drugs during the study. Ethics
Committee approval from all participating centers was
obtained, and all patients gave their written informed
consent to participate.
Treatment assignment
Patients were randomly assigned to one of the following
three groups with a ratio of 1:1:1: (1) placebo 2 × 3 caps/
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day, (2) bio-optimized Curcuma longa extracts (BCL)
low dosage 2 × 2 caps/day plus placebo 2 × 1 cap/day,
and (3) BCL high dosage 2 × 3 caps/day. Capsules were
taken twice daily with water, once at breakfast and once
at dinner for 3 months. This pharmaceutical-grade BCL
has received approval from Belgian Competent Author-
ities (PL 31/100; Federal Public Service, Health, Food
Chain Safety and Environment) and commercialized
under the brand name FLEXOFYTOL® (Tilman SA,
Baillonville, Belgium). The capsule of BCL available on
the market was encapsulated to allow for a double-blind
design. The allocation sequence was created by re-
stricted blocking randomization, with a block size of 6.
To achieve a good balance between the treatments deliv-
ered to each center, investigation kits were shipped by
blocks, which were multiple of 3. The investigator was
asked to distribute the blinded kit by following the
randomization sequence, in order to achieve a good bal-
ance between the three treatment groups within this
center. Each capsule contained 46.67 mg of turmeric rhi-
zome extract (Curcuma longa L.), Polysorbate 80 [E433]
as an emulsifier, and citric acid [E330] as an acidity regu-
lator. Placebo capsules contained sunflower seed oil. For
rescue analgesia, patients were allowed to take paraceta-
mol 500 mg tablets (maximum dosage 3 g/day) or oral
NSAIDs if paracetamol was insufficient. An appropriate
washout period of 24 h was required before symptom as-
sessment at in-clinic visits. No other pharmacological or
non-pharmacological interventions for OA were allowed.
Compliance with the study treatments was established
by counting unused study products. Usual treatments
taken by the patient in other non-OA-related diseases
were allowed; anticoagulants (coumarinic compounds)
and heparin were forbidden.
Outcome measures
There were two co-primary endpoints, and both were
assessed as the change from baseline, that is, the differ-
ence between the enrollment and study conclusion. One
endpoint was the Patient Global Assessment of Disease
Activity (PGADA) on a 100-mm visual analog scale
(VAS). The other endpoint was the serum levels of
Coll2-1 (sColl2-1), a specific amino acid sequence located
in the triple helicoidal part of type II collagen and consid-
ered as a biomarker of cartilage degradation [24, 25].
sColl2-1 was measured in diluted serum using an enzyme-
linked immuno-sensitive assay ELISA method (Artialis SA,
Liège, Belgium). The secondary endpoints included the pa-
tient’s estimate of pain on a 100-mm VAS, the Knee injury
and Osteoarthritis Outcome Score (KOOS) index, and its
subscale scores using a self-administered questionnaire.
Paracetamol/NSAID consumption during the month prior
to each visit and patients’ satisfaction with the treatment
using a 5-point ordinal Likert scale (better, little better,
none, little lower, or far lower). All adverse events (AE) and
abnormal laboratory test results were recorded.
Statistical analysis
Statistical analyses have been carried out following the
recommendations and guidance on statistical principles
for clinical trials (Sakpal, 2010; ICH E9) (Additional file 2).
The sample size was considering the results obtained in a
previous pilot study [26]. We calculated a sample size of
50 patients per group (150 patients in total) based on a
difference in Coll2-1 biomarker level of 44.4 nmol/l with a
standard deviation of 53 and a difference in patient assess-
ment of global disease activity of 21mm with a standard
deviation of 25, an alpha risk of 2.5% (to take into account
multiplicity due to co-primary endpoints), a power of
85%, and a dropout rate of 15%. Mixed model (repeated
measures ANCOVA model) followed by post hoc adjust-
ments test was used to evaluate the efficacy of primary
and secondary target variables. p values for treatment ef-
fect, time effect, and the effect of their interaction were
considered significant at the 2.5% alpha level for co-pri-
mary endpoints (p < 0.025) and at the 5% alpha level for
the secondary endpoints (p < 0.05).
As no difference between the BCL treated groups was
seen at baseline and at 3 months and as curcumin levels
in the serum were not significantly different between
BCL doses, pooled values of the BCL-treated groups
were also considered. PGADA and sColl2-1 from base-
line to month 3 were compared between the three treat-
ment groups by means of a linear mixed model. In some
situations, a log transformation has been considered for
achieving normal distribution of the outcome of interest.
Within the longitudinal framework, between-group dif-
ferences have been investigated at each time point using
classical post hoc test. Differences in the distribution of
qualitative criteria between the treatment groups have
been analyzed using the chi-square (χ2) test. Compliance
has been evaluated by the pill count method, as well as
in percentage of the estimated versus theoretical con-
sumption. Post hoc analysis included the longitudinal
analyses of sColl2-1, PGADA, VAS pain, and KOOS
using raw data and absolute difference; the longitudinal
analyses of Coll2-1, PGADA, and patient’ estimated pain
using pooled values of the BCL-treated groups; and the
longitudinal analyses of PGADA and VAS pain using ad-
justed value for the intake of rescue treatment. All re-
sults were considered to be significant at the 5% critical
level (p < 0.05). Statistical analyses were carried out using
the Statistical Analysis System (SAS version 9.4, SAS In-
stitute Inc., Cary, NC, USA). The following analysis pop-
ulations were defined for the study: the safety population
(SP) includes all patients treated with at least one dose
of the investigational product. The safety analysis was
based on the safety population. Intention to treat (ITT)
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population includes every subject who is randomized ac-
cording to randomized treatment assignment. Full analysis
set (FAS) population comprises of subjects who have one
efficacy basal measure and at least one corresponding
post-baseline efficacy measurement for one of the main ef-
ficacy variables, regardless of subsequent withdrawal from
treatment or deviation from the protocol. Per-protocol
(PP) population included all treated subjects who had not
suffered any major protocol deviation.
Results
One hundred fifty patients were randomized and consid-
ered eligible for the ITT analysis and 141 for the FAS
analysis. Among the FAS population, 49 received a high
dose of BCL, 47 received a low dose of BCL, and 45 re-
ceived placebo (Fig. 1). The cumulative time distribution
of withdrawals was similar in the three groups without
significant differences in the reasons for withdrawals. At
baseline, participants in each group were well-matched
(Table 1). Grades II to IV of KL were equally distributed
between the three groups, with 99% of grade II and III.
At inclusion, 92.2% of patients were taking paracetamol
and 71.6% NSAIDs. All the patients were using paraceta-
mol and/or NSAIDs during the study period. The major-
ity (82.3%) of paracetamol and NSAID consumers were
taking these drugs between 7 to 14 days a month.
ANCOVA model for repeated measures was performed
to analyze the two co-primary endpoints as well as the
secondary endpoints on FAS and PP populations. Longitu-
dinal differences such as pain relief and improvement of
PGADA were detected for all groups, but no significant
difference between the treatment was highlighted. Results
for FAS population were shown in Additional file 1: Table
S1. Nevertheless, post hoc tests revealed interesting results
and were presented here after.
Analysis of PGADA on the ITT population revealed a
significant improvement in all treatment arms compared
with time (all groups p < 0.0001), but the time evolution
curves were found comparable (Fig. 2a). Analysis of ab-
solute difference between baseline and time points on
the pooled treated patients in FAS revealed a signifi-
cantly greater reduction of PGADA in treated patients
than in the placebo group at T1 and T3 (p = 0.016 and
p = 0.027, respectively) (Fig. 2b, c).
Fig. 1 Disposition of patients. BCL, bio-optimized Curcuma longa; FAS, full analysis set; ITT, intention to treat; PP, per-protocol; AE, adverse event
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Table 1 Demographic and baseline characteristics of patients
BCL high dose, N = 49 BCL low dose, N = 47 Placebo, N = 45
Age (years)
Mean (SD) 60.9 (9.78) 61.4 (7.49) 63.3 (7.69)
Sex, n (%)
Female 39 (79.6) 40 (85.1) 34 (75.6)
BMI (kg/m2)
Mean (SD) 29.4 (4.87) 30.4 (5.23) 29.4 (5.2)
Time from diagnosis of knee OA (years)
Mean (SD) 7.41 (7.294) 6.6 (4.671) 7.6 (9.3)
KL grade, n (%)
Grade I 0 (0.0%) 0 (0.0%) 0 (0.0%)
Grade II 31 (63.3%) 27 (57.4%) 29 (64.4%)
Grade III 18 (36.7%) 19 (40.4%) 16 (35.6%)
Grade IV 0 (0.0%) 1 (2.0%) 0 (0.0%)
Target knee (the most symptomatic), n (%)
Right 27 (55.1%) 22 (46.8%) 25 (55.6%)
Target knee pain (VAS, mm)
Mean (SD) 62.9 (13.8) 63.3 (15.8) 59.9 (12.3)
PGADA (VAS, mm)
Mean (SD) 67.2 (17.5) 69.6 (17.8) 63.9 (17.3)
Coll2-1 (nM)
Mean (SD) 393.39 (165.2) 373.8 (133.5) 384.7 (122.0)
Ultra-sensitive CRP (mg/l)
Mean (SD) 2.5 (2.5) 3.4 (2.9) 3.2 (2.8)
Rescue treatment (NSAIDs) in the last month, n (%)
No 15 (30.6%) 12 (25.5%) 13 (28.9%)
Less than 7 days 5 (10.2%) 2 (4.3%) 2 (4.4%)
7 to 14 days 15 (30.6%) 19 (40.4%) 16 (35.6%)
15 to 21 days 4 (8.2%) 9 (19.1%) 5 (11.1%)
More than 21 days 7 (14.3%) 2 (4.3%) 6 (13.3%)
Every day 2 (4.1%) 3 (6.4%) 3 (6.7%)
NI 1 (2.0%) 0 (0.0%) 0 (0.0%)
Rescue treatment (paracetamol) in the last month, n (%)
No 6 (12.2%) 3 (6.4%) 2 (4.4%)
Less than 7 days 1 (2.0%) 3 (6.4%) 2 (4.4%)
7 to 14 days 27 (55.1%) 18 (38.3%) 21 (46.7%)
15 to 21 days 3 (6.1%) 11 (23.4%) 8 (17.8%)
More than 21 days 4 (8.2%) 6 (12.8%) 7 (15.6%)
Every day 8 (16.3%) 6 (12.8%) 5 (11.1%)
NI 6 (12.2%) 3 (6.4%) 2 (4.4%)
KOOS—global score
Mean (SD) 199.2 (68.1) 201.5 (73.5) 197.7 (60.0)
KOOS—pain
Mean (SD) 45.3 (16.4) 45.8 (15.6) 44.2 (13.9)
KOOS—ADL
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Analysis of sColl2-1 on the ITT population showed in
the placebo and BCL low-dose groups, but not in the
BCL high-dose group, a transient but non-significant in-
crease of sColl2-1 between T0 and T1. Thereafter, in all
groups, sColl2-1 decreased between T1 and T3 (all p <
0.01), but no difference between the groups was found
(Fig. 3a). Of note, the baseline level of sColl2-1 was simi-
lar between the groups. Using pooled values for the
treated groups (BCL high plus low doses) on PP popula-
tion, an absolute difference of sColl2-1 between baseline
and T3 revealed a significant difference between the
pooled BCL groups and placebo (P = 0.031) (Fig. 3b, c).
In ITT, knee pain on VAS significantly decreased with
time (p < 0.001) in both BCL high and low doses (Fig. 4)
while significance was not achieved after 3 months in
the placebo group (p = 0.051). At T3, a significant dif-
ference was observed in ITT between both BCL high
dose and low dose and placebo (both p = 0.018), while
no significant difference was found between both BCL
doses (p = 0.9002). The absolute difference between
baseline and time points was significantly more im-
portant in the BCL groups than in placebo at T1
(high dose − 16 mm, low dose − 16.5 mm, placebo − 4
mm; p = 0.046) and T3 (high dose − 29.5 mm, low
dose − 36.5 mm, placebo − 8 mm; p = 0.032). The im-
provement in pain observed in the BCL low-dose
group corresponds to an effect size (ES) of 0.35 for
pain at T1 and 0.43 at T3.
KOOS global score and subscales were significantly
improved over time in all groups (p < 0.001), and the
evolution was found comparable within the three groups
in the FAS population (Table 2). Although KOOS global
score and subscale changes to T1 and T3 tended to be
more important in the BCL groups, no significant differ-
ence between the groups was found.
Study of compound usage was > 80% in all groups and
comparable in the placebo and BCL groups, demonstrat-
ing excellent compliance. This was confirmed by curcu-
min measurement in PP. Curcumin serum levels
dramatically increased at T1 (p < 0.001) and then
remained stable until T3 in the low BCL group (p =
0.639) while undetectable in the placebo group (p =
0.948)(Fig. 5). At T1, but not at T3, curcumin levels
were significantly higher in BCL high dose than in BCL
low dose (p = 0.034).
Finally, there were significantly more adverse events
(AE) related to the product in the BCL high dose than
in the BCL low dose and placebo (37%, 21%, 13%,
Table 1 Demographic and baseline characteristics of patients (Continued)
BCL high dose, N = 49 BCL low dose, N = 47 Placebo, N = 45
Mean (SD) 49.8 (17.9) 48.9 (17.3) 48.9 (16.6)
KOOS—QoL
Mean (SD) 32.0 (18.7) 31.5 (19.2) 33.3 (18.1)
KOOS—symptoms
Mean (SD) 52.15 (15.9) 52.8 (15.6) 54.1 (13.5)
KOOS—Sport and rec.
Mean (SD) 19.5 (17.1) 19.8 (19.8) 17.2 (14.5)
ADL activity of daily life, BMI Body Mass Index, NSAID non-steroidal anti-inflammatory drug, KL Kellgren-Lawrence, NI no information, OA osteoarthritis, PAGDA
Patient Global Assessment of Disease Activity, QoL Quality of life, SD Standard Deviation, VAS Visual Analog Scale
Fig. 2 a Patients Global Assessment of Disease Activity (PGADA) assessed with a VAS evolution with time. b Comparison of the absolute
difference of PGADA between T0 and T1 in the placebo and pooled low- and high-dose BCL groups. c Comparison of the absolute difference of
PGDA between T0 and T3 in the placebo and pooled low- and high-dose BCL groups
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respectively, p = 0.012). No difference between BCL low
dose and placebo was observed. There were no more AE
leading to withdrawal in the BCL groups than in pla-
cebo. Abdominal discomfort and diarrhea were the most
frequently reported AE. Routine laboratory testing did not
identify any abnormalities in hepatic or renal dysfunction.
The mean paracetamol or NSAID intake decreased
with time in all groups, but no significant difference was
observed between the groups at different time points.
While global analyses did not reveal any significant dif-
ference between the groups at different time points,
complementary analyses on FAS population, covering
within-group difference, revealed that only subjects of
the BCL high-dose group showed a significant decrease
in the intake frequency of paracetamol at different time
points (p = 0.031 at T1, p = 0.0016 at T3) while no vari-
ation with time was observed in the low-dose and
placebo group. For NSAIDs, a significant decrease of in-
take frequency was observed only in the low-dose
group (p = 0.038 at T1, p = 0.029 at T3).
Discussion
In this paper, we report the data of a phase II clinical
trial investigating the clinical efficacy of two doses of a
bio-optimized curcuminoids extract, administered orally
during 3 months in patients with symptomatic estab-
lished knee OA. To our knowledge, this is the first study
supporting some therapeutic effect of bio-optimized cur-
cumin in knee OA in a well-designed prospective multi-
center trial. Indeed, some recent meta-analyses have
pointed out the poor quality of clinical trials investigat-
ing food supplements including curcuminoids extracts
[20, 21]. The data indicate that BCL, as an adjuvant
treatment to paracetamol and/or NSAIDs, is superior to
placebo to decrease pain and PGADA from the first
month of treatment. The improvement in pain observed
in the BCL low-dose group corresponds to an effect size
(ES) of 0.35 for pain at T1 and 0.43 at T3. ES ≤ 0.2 is
usually considered as small while ES between 0.2 and 0.5
is defined as medium. This corroborates the results of
previous studies suggesting beneficial effects of curcu-
min on pain in rheumatoid arthritis [22]. This analgesic
effect is all the more remarkable as it is observed in pa-
tients who used paracetamol and NSAIDs before and
during the study. This means that in our population,
BCL has an analgesic effect on top of the expected effect
of paracetamol and NSAIDs. Interestingly, NSAID con-
sumption decreased in the low-dose group over time,
suggesting that at low dose, BCL decreases pain and
NSAID consumption. Considering the adverse effects of
NSAIDs, mainly in patients with co-morbidities, BCL
could be of value as an alternative to NSAIDs in OA
treatment [27, 28]. Surprisingly, no significant difference
was observed with the KOOS. This can be explained by
the fact that KOOS was evaluated on a 5-point Likert
Fig. 3 a Serum levels of Coll2-1 evolution with time. b Comparison of the absolute difference of sColl2-1 between T0 and T1 in the placebo and
pooled low- and high-dose BCL groups. c Comparison of the absolute difference of sCOll2-1 between T0 and T1 in the placebo and pooled low-
and high-dose BCL groups
Fig. 4 Knee pain assessment with a VAS evolution with time
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scale while knee pain was recorded using a visual analog
visual scale of 100 mm which has a better ability to de-
tect clinical change than the Likert scale [29].
One strength of this study was that curcumin levels
have been measured in the blood of subjects to evaluate
the compliance and the bioavailability of the product.
Curcumin levels raised rapidly in the blood of all treated
patients while remained undetectable in the placebo
group. Another key observation was that the molecule
reached a steady state after 1 month. In addition, plateau
curcumin levels were comparable in the high- and low-
dose BCL groups. This finding provides some indication
of why both doses showed similar effects on pain. This,
combined with the observation that the number of ad-
verse effects related to the product was increased in the
high BCL group, justifies the use of low-dose BCL in
OA management. This also explains the higher drop-out
in the high BCL group. The observed adverse effects
were mainly diarrhea. In pharmacological terms, curcu-
min is a complete choleretic-cholagogue. The cleavage
products of curcumin (feluric and hydrofeluric acids)
have cholecistokinetic properties because they squeeze
the gallbladder, while another principle product, para-
tolilmethilcarbinol, has a strong choleretic activity. The
choleretic effect of curcumin increases bile production
by approximately 62% [30].
Post hoc analyses have also demonstrated that serum
Coll2-1, a biomarker of type II collagen degradation, de-
creased in the BCL groups while slightly increased in the
placebo group [24, 25]. Of course, this observation has
to be verified in a larger population, and it remains to be
demonstrated that this is associated with changes in
structural parameters by imaging but suggest that BCL
could downregulate cartilage catabolism and could
therefore slow down structural progression.
This study showed some limitations. The main one is
the small sample size. It is clear that larger sample sizes
are required to confirm the positive trends observed in
this study. The second limitation was the particularities of
the study population. Indeed, the study population in-
cluded patients with continuous pain despite the frequent
intake of paracetamol and/or NSAIDs thus predominantly
non-responders to standard OA pain treatment and thus
not very sensitive to anti-inflammatory treatment.
Table 2 KOOS changes between the follow-up visits (T3 and T1) and baseline FAS population
BCL high dose,
mean ± SD
BCL low dose,
mean ± SD
Placebo,
mean ± SD
KOOS change at T1 (difference between T1
and baseline)
N 49 46 45
Global score 35.2 ± 67.5 18.0 ± 57.6 7.9 ± 60.2
Pain 7.1 ± 17.5 4.8 ± 16.7 3.1 ± 13.9
Symptoms 6.7 ± 15.2 2.9 ± 13.6 1.7 ± 14.6
Function in daily living (ADL) 5.9 ± 19.6 4.0 ± 16.5 1.4 ± 13.2
Function in sport and recreation
(sport/rec)
10.5 ± 18.0 4.2 ± 16.7 2.3 ± 15.4
Knee-related quality of life (QoL) 5.6 ± 14.8 3.1 ± 14.9 − 0.2 ± 16.2
KOOS change at T3 (difference between T3
and baseline)
N 47 38 40
Global score 56.3 ± 82.6 48. ± 73.1 42.1 ± 66.2
Pain 12.3 ± 19.4 12.8 ± 18.4 10.8 ± 16.5
Symptoms 10.0 ± 16.6 7.4 ± 16.0 7.5 ± 14.7
Function in daily living (ADL) 9.2 ± 19.5 10.3 ± 20.9 7.3 ± 14.6
Function in sport and recreation
(sport/rec)
11.1 ± 20.5 9.6 ± 15.3 9.7 ± 17. 8
Knee related quality of life (QoL) 12.4 ± 20.3 9.2 ± 19.3 6.6 ± 16.8
Fig. 5 Curcumin levels in the serum of patient receiving daily doses
of BCL or placebo
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Conclusions
In conclusion, this study provided evidence that daily in-
take of 186.6 mg/day of BCL in patients with symptom-
atic knee OA leads to a reduction in pain superior to
placebo with a good safety profile and a good compli-
ance, despite the use of paracetamol and/or NSAIDs.
Moreover, this trial provides useful information for the
design of a larger phase III clinical trial including the
sample size estimate, the choice of the dose, and the se-
lection of primary outcomes.
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